Prescient Therapeutics (ASX: PTX) is pleased to announce the successful completion of the manufacturing and delivery of crucial components of the OmniCAR platform for Prescient’s in-house programs of next-generation CAR-T therapies. 

A range of binders against a variety of cancer targets, including CLL-1; CD33; Her2 and EGFRviii, have been manufactured by a leading US antibody manufacturer. All binders have incorporated SpyTag, which is required for covalent binding to immune cells (such as T-cells) in the OmniCAR system.

Additionally, Prescient has also received delivery of lentiviral vectors that will be used to produce CAR-T cells expressing SpyCatcher. Lentiviral vectors are a rate-limiting step in CAR-T production. Together the SpyTagged binders and CAR-T cells expressing SpyCatcher form the basis for the unique, modular OmniCAR platform.

The Company’s shares traded higher today, hitting an intraday all time high of 25.5c and closing at a record close of 24.5c.

The Company’s last capital raise was undertaken less than 12 months ago at 5.5c.

Reach Markets will be hosting an investor briefing with PTX CEO Steven Yatomi-Clarke tomorrow to discuss progress with the OmniCAR research programs and Peter MacCallum Cancer Centre partnership. We will also be joined by Professor Phil Darcy from Peter Mac and Prescient’s Director of Scientific Affairs, Dr Rebecca Lim. There will also be a live Q&A. Click here to register.

Announcement Highlights:

• Prescient has incorporated SpyTag into a range of binders for its three next generation CAR-T programs
• Prescient has also received delivery of lentiviral vectors that will be used to produce CAR-T cells expressing SpyCatcher
• The SpyTag binders and CAR-T cell expressing SpyCatcher are the novel components for Prescient’s unique next generation OmniCAR platform

“Demonstrating that novel components can be manufactured is a crucial milestone in the development of an innovative next-generation CAR platform like OmniCAR. Successfully producing binders for CLL-1; CD33; Her2 and EGFRviii will enable our research team to produce CAR-T cells for our three in-house programs. We are also pleased to have timely delivery of lentiviral vectors, which is rate-limiting in manufacturing CAR-Ts and have proven to be a bottleneck for many developers.” 

“Prescient’s research team at the Peter Mac has completed all the preparatory work in parallel, and the delivery of the binders and vectors now enables the team to progress the development of our in-house next-generation cell therapies.”

To stay updated with the latest company news and announcements, like the one mentioned above, please register your interest on PTX’s investor centre. 

Reach Markets have been engaged by PTX to help manage their investor communications.

Sources:

• Prescient Therapuetics, PTX Completes CAR-T Manufacturing Milestone for OmniCAR